After 13 years as President and CEO of Bavarian Nordic Peter Wulff has wished to
step down. Anders Hedegaard is appointed new President and CEO and will take up
his position November 1 or before.
Anders Hedegaard comes from a position as member of ALK-Abelló's Corporate
Management in charge of Business Operations.
Anders Hedegaard holds a M.Sc. degree in chemical engineering specialising in
molecular biology. Anders Hedegaard's management career includes executive
positions with Aga, Foss and Novo Nordisk.
Peter Wulff takes over a new position in Corporate Management as Head of
Business Development including existing end new scientific commercial activities
and projects.
Bavarian Nordic's Corporate Management hereafter consists of:
Anders Hedegaard (President & CEO)
Paul Chaplin (Executive Vice President, Research & Development and CSO)
René Djurup (Executive Vice President, Technical Operations and CTO)
Morten M. Rasmussen (Executive Vice President, Contracts, Legal and Intellectual
Property Rights)
Hans Christian Teisen (Executive Vice President, Finance and Commercial Affairs
and CBO)
Peter Wulff (Executive Vice President, Business Development)
Asger Aamund, Chairman of the Board, comments:
“Anders Hedegaard possesses the competence and profile we see as ideal to lead
Bavarian Nordic. During his international career Anders Hedegaard has built a
track record and a management experience which makes him qualified for the
position as CEO of Bavarian Nordic.
Since its inception 13 years ago, Bavarian Nordic has been synonymous with Peter
Wulff whose excellent results and total commitment successfully have landed
Bavarian Nordic in its present position as an internationally leading vaccine
manufacturer.
The Board of Directors is delighted to welcome Peter Wulff as new Executive Vice
President in charge of Business Development.
Kvistgård, 19 April 2007
Asger Aamund
Chairman
Contacts: Peter Wulff, President & CEO
Telephone: +45 33 26 83 83
Media:
United Kingdom
Mary Clark, Capital MS&L
Telephone: +44 207 307 5330
United States of America
Elizabeth Dempsey Becker, Bavarian Nordic Inc.
Telephone: +1 202 536-1576
About Bavarian Nordic A/S:
Bavarian Nordic (CSE: BAVA) is a leading international biopharmaceutical company
developing and producing innovative vaccines to prevent and treat infectious
diseases and cancer. With operations in Denmark, Germany, the USA, and
Singapore, Bavarian Nordic employs over 200 people. Bavarian Nordic's patented
technology, MVA-BN®, is as been demonstrated in clinicial studies, one of the
world's safest, multivalent vaccine vectors for the development of vaccines
against various infectious diseases such as smallpox, HIV/AIDS, as well as
against breast and prostate cancer. Several MVA-BN®-based HIV and smallpox
vaccines are in clinical Phase I and Phase II trials. Bavarian Nordic has
ongoing development contracts with the US government to develop IMVAMUNE® as a
safe third-generation smallpox vaccine. Bavarian Nordic has supplied several
other governments with smallpox vaccines.
For more information please visit www.bavarian-nordic.com
“Safe Harbour" Statement Under the Private Securities Litigation Reform Act of
1995:
Except for the historical information contained herein, this release contains
"forward-looking statements" within the meaning of the Private Securities
Reform Act of 1995. No "forward-looking statement" can be guaranteed, and
actual results may differ materially from those projected. Bavarian Nordic
undertakes no obligation to publicly update any "forward-looking statement",
whether as a result of new information, future events, or otherwise. Additional
information regarding risks and uncertainties is set forth in the current
Annual Report, which we incorporate by reference.
Stockwise Resumé
Anders Hedegaard appointed new CEO of Bavarian Nordic. Peter Wulff stays on in
Corporate Management as Head of Business Development.
--------------------------------------------------------------------------------
| | Anders Hedegaard (born 1960). |
| | M. Sc. in Chemical Engineering. |
| | From 2002-2007 Anders Hedegaard was Executive Vice |
| | President, Business Operations & International |
| | Marketing at ALK-Abelló A/S. From 2000-2002 he was |
| | Group Vice President and Member of Group Management |
| | in Foss A/S. From 1991-2000 he worked with Novo |
| | Nordisk A/S in various management positions, |
| | departing as International Marketing Director. |
| | At Novo Nordisk A/S Anders Hedegaard played an |
| | important role in the launch of several key products. |
--------------------------------------------------------------------------------
Anders Hedegaard appointed new CEO of Bavarian Nordic. Peter Wulff stays on in Corporate Management as Head of Business Development
| Source: Bavarian Nordic A/S
Attachments
